A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

A novel crystalline form is defined by diffraction angle 2 of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.040.3 g/ml, stirring the suspension at 4050 C. for a period of time, and then cooling to 515 C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

A novel crystalline form is defined by diffraction angle 2 of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.040.3 g/ml, stirring the suspension at 4050 C. for a period of time, and then cooling to 515 C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.